Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf Holdings's revenue per share for the
three
months ended in Mar. 2026 was $1.23.
Curaleaf Holdings's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.99.
Warning Sign:
Curaleaf Holdings Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Curaleaf Holdings was -6.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -3.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Curaleaf Holdings's Revenue per Share or its related term are showing as below:
CURLF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3 Med: 38.6 Max: 166.2
Current: -3
During the past 12 years, Curaleaf Holdings's highest 3-Year average Revenue Per Share Growth Rate was 166.20% per year. The lowest was -3.00% per year. And the median was 38.60% per year.
CURLF's 3-Year Revenue Growth Rate is ranked worse than 69.1% of 903
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs CURLF: -3.00
Curaleaf Holdings (OTCPK:CURLF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Curaleaf Holdings Revenue per Share Related Terms
Curaleaf Holdings Revenue per Share Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Curaleaf Holdings's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a Revenue per Share of $4.99 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Curaleaf Holdings and its competitors. According to the industry distribution chart, Curaleaf Holdings ranks #624 out of 903 companies in the Drug Manufacturers industry, placing it in the top 69.1%.
Is Curaleaf Holdings' Revenue per Share too high?
Curaleaf Holdings' current Revenue per Share is $4.99. The Drug Manufacturers industry median Revenue per Share is 3.80. Curaleaf Holdings' value of $4.99 is 31.3% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #624 out of 903 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Revenue per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #624 out of 903 companies for Revenue per Share. This places Curaleaf Holdings in the lower half of its industry. The industry median Revenue per Share is 3.80. Curaleaf Holdings' value of $4.99 is 31.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Revenue per Share of $4.99 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Revenue per Share is $4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.04, compared to a current price of $8.91 — trading 10.8% above its estimated fair value. The current Revenue per Share is $4.99 and 31.3% above the Drug Manufacturers industry median of 3.80. Curaleaf Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Revenue per Share is $4.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $8.91 is trading 10.8% above its estimated GF Value™ of $8.04.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Revenue per Share: $4.99
GF Value™: $8.04 vs. price of $8.91 (10.8% above fair value)
Industry Position: 31.3% above the Drug Manufacturers median (#624 of 903)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
72GF Score
Get the complete analysis for CURLF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
